Is Your Paper Ready for eLife? The Open Science Publishing Model

This is where eLife diverges most sharply from every other journal you've submitted to. In a traditional journal, your paper goes through peer review behind closed doors. If it passes, it gets published. If it doesn't, you start over somewhere else. Nobody outside the process sees the reviews.

eLife flips this. After peer review, the journal publishes the reviewer assessments publicly. Your paper can then be posted as an "assessed preprint," meaning it's available for anyone to read alongside expert evaluations of its strengths and weaknesses. You, the author, can then decide whether to revise the work and pursue formal publication or let the assessed preprint stand on its own.

This model changes the incentives in ways that matter. Reviewers know their assessments will be public, which tends to make reviews more constructive and less adversarial. Authors get credit for their work even if they don't clear every revision hurdle. And readers get to see what experts actually thought about the paper, rather than assuming that "published" means "flawless."

The practical implication for you as a submitting author: your work will be evaluated in public. If the reviewers identify a fatal flaw, that assessment will be visible. If they praise your methodology but flag a limitation, that praise and that limitation will both be on the record. This transparency is either a feature or a bug depending on your comfort level. For researchers doing careful, reproducible work, it's overwhelmingly a feature.

Let's address the elephant in the room. eLife's IF of 6.4 puts it below Nature Communications (14.7), PLOS Biology (9.8), and several other journals that publish similar work in biology and medicine. If you're in a department or country where impact factors drive hiring and promotion decisions, this gap is real and you shouldn't pretend it doesn't exist.

But context matters. eLife is a non-profit, open-access publisher that has deliberately deprioritized impact factor as a measure of journal quality. The assessed preprint model, by design, changes how papers accumulate citations. When a paper is available as a preprint with public reviews before it reaches its "final" form, the citation patterns differ from a paper that only becomes visible upon formal publication.

There's also a philosophical question. eLife's editorial team has argued, with some justification, that impact factor measures journal popularity more than it measures the quality of individual papers. A Nature paper with 3 citations and an eLife paper with 300 citations exist in the same world, and the IF tells you nothing about which one contributed more to its field.

None of this changes the political reality of academic career progression. If your tenure committee counts impact factors, you need to factor that in. But if you're at a stage where the quality and visibility of your specific paper matter more than the journal's aggregate metric, eLife becomes a much more interesting option.

Most journals charge article processing charges after acceptance. You submit, you get reviewed, and if your paper is accepted, you pay. The financial risk is limited because you only pay for successful outcomes.

eLife doesn't work this way. The $3,000 fee is charged when the editors decide to send your paper for external review. If the reviewers then find problems and you can't address them, if you decide not to revise, if the paper doesn't ultimately reach formal publication, you've still paid. The money doesn't come back.

This model exists for a reason. eLife argues that tying payment to acceptance creates perverse incentives. Journals that only get paid when they accept papers have a financial reason to accept more papers. By charging at the review stage, eLife removes that incentive. The editors can commit to reviewing your paper without any financial pressure to ultimately accept it.

From your perspective as an author, this means you should be highly confident in your paper before it reaches the review stage. The good news is that editorial screening (which happens in 5-7 days and doesn't cost anything) filters out roughly 50-60% of submissions. If your paper passes screening and enters review, the editors have already made a meaningful judgment that it's worth evaluating. But "worth evaluating" and "will be accepted" aren't the same thing, and you're paying for the evaluation regardless.

The $3,000 figure is also worth comparing to other journals. Nature Communications charges roughly $6,490. PNAS charges around $5,200 for their open access option. Science Advances comes in at about $4,500. At $3,000, eLife's fee is lower in absolute terms, but the fee-at-review structure means you're paying in a higher-risk scenario.

To make a strategic decision about where to submit, it helps to see eLife alongside journals that occupy similar territory in biology and medicine.

A few patterns emerge. eLife has the lowest impact factor in this group but also one of the lowest APCs. It's the only journal that charges before acceptance and the only one with a fully public assessed preprint model. Nature Communications has a much higher IF and acceptance rate but costs twice as much and is run by a for-profit publisher (Springer Nature).

The question you need to ask isn't "which journal has the highest IF?" It's "which journal aligns with how I think science should be communicated, given the practical constraints I'm working under?"

eLife's editorial priorities are different from most high-profile journals, and understanding this difference will save you time.

Data quality over novelty claims. This is the single most important thing to understand about eLife. Most top-tier journals want you to tell a story about why your finding is new and why it matters. eLife wants you to show that your data is rock-solid. Papers with exceptional datasets, rigorous controls, and reproducible methods consistently do better at eLife than papers with bold claims supported by thinner evidence.

This doesn't mean novelty is irrelevant. Your paper still needs to contribute something new. But eLife won't reject a careful, well-controlled study because the finding is "expected" if the data is outstanding. And it will reject a flashy result if the controls are inadequate.

Reproducibility signals. eLife pays close attention to whether your methods section is detailed enough for someone else to repeat your experiments. Are reagents specified with catalog numbers? Are analysis scripts available? Is raw data deposited? These aren't afterthoughts at eLife. They're part of the editorial evaluation.

Transparent reporting. Pre-registration, registered reports, power analyses, and other transparency practices are valued. You don't need all of these, but having any of them strengthens your submission.

Biological or medical significance. Your work needs to address a question that matters to the biology or medicine community. Technical advances are welcome, but they need to be demonstrated in the context of a real biological question, not presented as method papers in isolation.

With 50-60% of papers desk-rejected, the editorial screening is the first real hurdle. eLife's screening happens fast, typically within 5-7 days. This is quicker than most comparable journals.

During screening, editors evaluate whether your paper fits eLife's scope, whether the claimed contribution is significant enough to warrant review, and whether there are obvious methodological red flags. The speed of screening means editors are making relatively quick judgments, so first impressions matter.

Your title and abstract carry disproportionate weight during screening. If your abstract buries the key finding in the fourth paragraph, or if your title is vague, you're making the editor's job harder. Lead with what you found, not with what you studied. "CRISPR-Cas9 editing of gene X restores function Y in Z disease model" tells the editor more than "Investigation of gene X in disease Z."

Your cover letter should explain, concisely, why this paper fits eLife specifically. Mention the data quality emphasis. Reference the assessed preprint model if it's relevant to your work. Show that you understand what makes eLife different from the ten other journals you could have submitted to.

If your paper passes screening, external review typically takes 28-42 days. This is fast by journal standards. eLife achieves this partly through its editorial model (active academics serve as reviewing editors, not just as advisory board members) and partly through its technology platform.

Reviews at eLife tend to be detailed and constructive. Reviewers know their assessments will be published publicly, which changes the tone. You're less likely to get the anonymous "reject because I don't like this lab's approach" review that plagues many journals. You're more likely to get specific, actionable feedback on methodology, analysis, and interpretation.

After review, eLife issues an assessment that includes an evaluation summary (the editors' overview), public reviews (the individual reviewer reports), and recommendations for authors (which may include suggestions for revision). All of this becomes part of the public record if you proceed with the assessed preprint pathway.

Your data is your strongest asset. If you've generated a truly exceptional dataset with thorough controls and reproducible protocols, eLife will value that more than most journals. The assessed preprint model also means your data gets visibility quickly.

You support open science principles. If you believe in public peer review, preprint-first publishing, and transparent evaluation, eLife puts those values into practice. Submitting here is a statement about the kind of science you want to do.

You're in biology or medicine with a well-defined question. eLife's scope is narrower than Nature Communications or PNAS. If your work falls cleanly within biology or medicine, that focus works in your favor. You won't be competing with physicists and engineers for editorial attention.

The APC budget is tight. At $3,000, eLife is cheaper than most comparable journals. The fee-at-review risk is real, but if your paper passes screening (meaning the editors believe it's worth reviewing), the overall cost is lower than alternatives.

You need the highest possible impact factor. If your career depends on publishing in journals with IFs above 10, eLife's 6.4 won't help. This isn't a commentary on eLife's quality. It's a reality of how many institutions evaluate researchers.

Your paper relies more on narrative than data. Some papers are strong because they synthesize existing knowledge in new ways or propose theoretical frameworks. eLife's emphasis on data quality and reproducibility means these papers may find a tougher audience here than at journals that value conceptual novelty.

You're uncomfortable with public reviews. If the thought of your reviewer reports being visible to anyone, including future collaborators, competitors, and hiring committees, makes you nervous, think carefully before submitting. The transparency is permanent.

Your work falls outside biology and medicine. eLife doesn't publish chemistry, physics, engineering, or social science papers. If your work is interdisciplinary, make sure the biological or medical component is central, not peripheral.

eLife uses its own submission system at submit.elifesciences.org, not Editorial Manager or ScholarOne. The interface is relatively straightforward, but give yourself time to familiarize with it before your submission deadline.

A few specific tips for eLife submissions:

Front-load your methods. Because eLife prioritizes data quality and reproducibility, your methods section needs to be exceptionally detailed. Don't treat it as an afterthought. Include enough detail that an independent lab could replicate your key experiments without contacting you.

Deposit your data early. eLife expects data to be in public repositories. If you're working with sequencing data (GEO or SRA), proteomics data (PRIDE), structural data (PDB), or any other data type with a standard repository, get it deposited before you submit. Include accession numbers in your manuscript.

Prepare for public scrutiny. Your figures, statistical analyses, and conclusions will all be evaluated in reviews that become public. Double-check everything. Run your statistics again. Make sure your figure labels are accurate. Small errors that might slide past reviewers at other journals become permanent public records at eLife.

Write for clarity, not for impressiveness. eLife's reviewer pool tends to appreciate clear, direct writing over jargon-heavy prose. State what you did, what you found, and what it means. Don't oversell.